Abstract
The essential nature of many metals is counterbalanced by the toxic effect that they can exert on both the eukaryotic and prokaryotic cell when not properly controlled. As such, virtually all organisms have developed regulatory systems that are required to maintain metal ion homeostasis. Helicobacter pylori is arguably the most successful bacterial pathogen in the world; the bacterium colonizes more than 50% of the worlds population. H. pylori lives in the acidic environment of the stomach and causes a persistent infection that results in disease sequelae such as gastritis, iron-deficiency anemia, ulcer disease and gastric cancer. A requirement of colonization is that the bacterium successfully competes with host cells for available metal ions. As such, it is perhaps no surprise that several crucial colonization factors utilize metal as an essential cofactor. Recent investigations into the absolute requirement for different metal ions and the need to manage their use have shown that metal ion homeostasis is achieved by H. pylori through the utilization of an intricate regulatory cascade that ensures metal uptake without toxic side effects. Herein we discuss this cascade, the role that individual metal ions play in H. pylori colonization and disease and the possibility that these metal homeostasis cascade components may serve as good targets for rational drug design to eradicate H. pylori infection.
Keywords: Helicobacter pylori, Cupriavidus metallidurans, homeostasis, Nickel metabolism, exbB-exbD-tonB operon
Current Medicinal Chemistry
Title: Balancing the Double-Edged Sword: Metal Ion Homeostasis and the Ulcer Bug
Volume: 14 Issue: 4
Author(s): Jeannette M. Whitmire, Hanan Gancz and D. Scott Merrell
Affiliation:
Keywords: Helicobacter pylori, Cupriavidus metallidurans, homeostasis, Nickel metabolism, exbB-exbD-tonB operon
Abstract: The essential nature of many metals is counterbalanced by the toxic effect that they can exert on both the eukaryotic and prokaryotic cell when not properly controlled. As such, virtually all organisms have developed regulatory systems that are required to maintain metal ion homeostasis. Helicobacter pylori is arguably the most successful bacterial pathogen in the world; the bacterium colonizes more than 50% of the worlds population. H. pylori lives in the acidic environment of the stomach and causes a persistent infection that results in disease sequelae such as gastritis, iron-deficiency anemia, ulcer disease and gastric cancer. A requirement of colonization is that the bacterium successfully competes with host cells for available metal ions. As such, it is perhaps no surprise that several crucial colonization factors utilize metal as an essential cofactor. Recent investigations into the absolute requirement for different metal ions and the need to manage their use have shown that metal ion homeostasis is achieved by H. pylori through the utilization of an intricate regulatory cascade that ensures metal uptake without toxic side effects. Herein we discuss this cascade, the role that individual metal ions play in H. pylori colonization and disease and the possibility that these metal homeostasis cascade components may serve as good targets for rational drug design to eradicate H. pylori infection.
Export Options
About this article
Cite this article as:
Whitmire M. Jeannette, Gancz Hanan and Merrell D. Scott, Balancing the Double-Edged Sword: Metal Ion Homeostasis and the Ulcer Bug, Current Medicinal Chemistry 2007; 14 (4) . https://dx.doi.org/10.2174/092986707779941069
DOI https://dx.doi.org/10.2174/092986707779941069 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Endoglin-Targeted Cancer Therapy
Current Drug Delivery Neuroinflammation and its Modulation by Flavonoids
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders
Current Pharmaceutical Design Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Morphological Characteristics, Geographical Distribution, Secondary Metabolites, and Biological Activities of Taxus
Mini-Reviews in Organic Chemistry Critical Functions of lncRNA DGCR5 in Cancers of the Digestive System
Current Pharmaceutical Design The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer
Current Cancer Therapy Reviews Xenobiotic and Non-Xenobiotic Interventions in the Microbiome Therapeutics
Current Drug Metabolism Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer
Recent Patents on Nanotechnology New Insights into the Regulation of Liver Inflammation and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin
Mini-Reviews in Medicinal Chemistry N-Myristoyltransferase: A Novel Target
Mini-Reviews in Medicinal Chemistry The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets